{
  "meta": {
    "title": "56_Anti-Rheumatoid_Drugs",
    "url": "https://brainandscalpel.vercel.app/56-anti-rheumatoid-drugs-494564bc.html",
    "scrapedAt": "2025-11-30T12:34:37.145Z"
  },
  "questions": [
    {
      "text": "A patient with rheumatoid arthritis has been on treatment for the past 15 years. During an annual eye check-up, her fundus appeared as shown in the picture given. Which of the following anti-rheumatoid drugs likely led to this side effect?",
      "choices": [
        {
          "id": 1,
          "text": "Cyclophosphamide"
        },
        {
          "id": 2,
          "text": "Methotrexate"
        },
        {
          "id": 3,
          "text": "Hydroxychloroquine"
        },
        {
          "id": 4,
          "text": "Leflunomide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image shows <strong>bull&rsquo;s eye maculopathy. </strong></p>\n<p><strong>Hydroxychloroquine</strong> use is associated with this side effect.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/53a773fdfa0041548e5b82487376e5de.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1311",
      "difficulty": "easy"
    },
    {
      "text": "A middle-aged woman with rheumatoid arthritis was on DMARD therapy with a drug that increases extracellular adenosine. Which drug was she likely on?",
      "choices": [
        {
          "id": 1,
          "text": "Methotrexate"
        },
        {
          "id": 2,
          "text": "Lefunamide"
        },
        {
          "id": 3,
          "text": "Sulphasalazine"
        },
        {
          "id": 4,
          "text": "Hydroxychloroquine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Methotrexate</strong> is the DMARD that<strong> increases extracellular adenosine.</strong></p>\n<p>It is a dihydrofolate reductase<strong> (DHFR) inhibitor</strong> that leads to purine synthesis inhibition and this is <strong>cytotoxic to lymphocytes</strong>.</p>\n<p>It also <strong>inhibits</strong> amino-imidazole carboxamide ribonucleotide&nbsp;<strong>(AICAR)</strong> transformylase and thymidylate synthetase. This leads to <strong>increased extracellular&nbsp;adenosine </strong>which is <strong>anti-inflammatory</strong>.</p>\n<p>The increased extracellular adenosine is<strong> hepatotoxic</strong>&nbsp;and hence monitoring with LFT is needed every 2-3 months.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c28e6d580919489d97a36f1f7b2db64ax1280x1432.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Uses of methotrexate (mnemonic: CANCER)</h3><p>Mnemonic: <strong>CANCER</strong></p>\n<p><strong>C</strong>rohn&rsquo;s disease</p>\n<p><strong>A</strong>bortion</p>\n<p><strong>N</strong>on-Hodgkin lymphoma, ALL</p>\n<p><strong>C</strong>horiocarcinoma, Sarcoma</p>\n<p><strong>E</strong>ctopic pregnancy</p>\n<p><strong>R</strong>heumatoid arthritis, Psoriasis, Vasculitis</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1301",
      "difficulty": "medium"
    },
    {
      "text": "A patient with rheumatoid arthritis on treatment with methotrexate came for a follow-up visit. Her peripheral blood smear shows the following finding. What drug can be administered to alleviate this side effect?",
      "choices": [
        {
          "id": 1,
          "text": "Ascorbic acid"
        },
        {
          "id": 2,
          "text": "Cyanocobalamin"
        },
        {
          "id": 3,
          "text": "Thiamine"
        },
        {
          "id": 4,
          "text": "Folinic acid"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The peripheral smear findings point to a diagnosis of <strong>megaloblastic anemia</strong>.<strong> Folinic acid</strong> is given with methotrexate to decrease its side effects.&nbsp;</p>\n<p><strong>Methotrexate</strong> is a&nbsp;dihydrofolate reductase <strong>(DHFR) inhibitor&nbsp;</strong>and thus can lead to a deficiency of folic acid which may present as megaloblastic anemia.</p>\n<p><strong>Folinic acid</strong>/leucovorin calcium/citrovorum factor is the <strong>5-formyl derivative of tetrahydrofolic acid</strong>. Thus, it decreases the side effects caused due to folate deficiency.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/650badba96cf4b7cb1b3c15c2f5a15a6.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8058",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs can be used for the treatment of a patient with rheumatoid arthritis?",
      "choices": [
        {
          "id": 1,
          "text": "Sulfacetamide"
        },
        {
          "id": 2,
          "text": "Sulfasalazine"
        },
        {
          "id": 3,
          "text": "Silver sulfadiazine"
        },
        {
          "id": 4,
          "text": "Mafenide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sulfasalazine</strong> can be used in the treatment of rheumatoid arthritis, as a <strong>conventional DMARD</strong>. It is also used in the management of ulcerative colitis and regional enteritis.</p>\n<p>Sulfasalazine is metabolized into the following:</p>\n<ul>\n<li><strong>5-amino salicylic acid </strong>(5-ASA) - it is not absorbed and is used to treat&nbsp;<strong>ulcerative colitis. </strong></li>\n<li><strong>Sulfapyridine</strong>&nbsp;- it is absorbed and is used to treat<strong>&nbsp;rheumatoid arthritis.</strong></li>\n</ul>\n<p>It is used as monotherapy in mild cases and as an add-on drug in moderate to severe cases.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1303",
      "difficulty": "easy"
    },
    {
      "text": "How does etanercept act?",
      "choices": [
        {
          "id": 1,
          "text": "Interleukin 1 inhibition"
        },
        {
          "id": 2,
          "text": "Interleukin 6 inhibition"
        },
        {
          "id": 3,
          "text": "TNF alpha inhibition"
        },
        {
          "id": 4,
          "text": "Janus kinase inhibition"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Etanercept</strong> acts by&nbsp;<strong>TNF alpha inhibition</strong>. It is a <strong>biological</strong> <strong>DMARD </strong>(disease-modifying anti-rheumatoid drug).</p><hr><h3>Related Pearl: Important drugs for rheumatoid arthritis</h3><p><strong>1) NSAIDs - </strong>analgesic and anti-inflammatory, used as <strong>adjunctive</strong> for management of uncontrollable <strong>symptoms</strong> and in acute <strong>flares.</strong></p>\n<p dir=\"ltr\"><strong>2) Glucocorticoids - </strong>used in acute <strong>flare</strong> for rapid control and as <strong>initial therapy</strong> before the onset of action of DMARDs. Chronic administration of low doses is needed in patients with inadequate response to DMARDs.</p>\n<ul>\n<li dir=\"ltr\">\n<p>Prednisolone - oral</p>\n</li>\n<li dir=\"ltr\">\n<p>Triamcinolone - intraarticular<br /> </p>\n</li>\n</ul>\n<p><strong><span>3) DMARDs - </span></strong><span>disease-modifying anti-rheumatoid drugs:</span></p>\n<p> </p>\n<p><strong>- Conventional DMARDs:</strong></p>\n<ul>\n<li dir=\"ltr\">Methotrexate (MTX)- is an antifolate drug. The DMARD of <strong>choice</strong> and the anchor drug for combination therapy. Regular <strong>LFT</strong> monitoring is required.</li>\n<li dir=\"ltr\">Hydroxychloroquine- is used as <strong>monotherapy</strong> for <strong>early</strong> and <strong>mild</strong> disease and in combination with other DMARDs for severe cases.</li>\n<li dir=\"ltr\">Sulfasalazine- is a salicylate. It <strong>reduces</strong> the radiographic <strong>progression</strong> of the disease.</li>\n<li dir=\"ltr\">Leflunomide- is a pyrimidine synthase inhibitor used as an <strong>alternative</strong> to MTX.</li>\n</ul>\n<p><span><strong>- Biologicals:</strong></span></p>\n<ul>\n<li>TNF-α antagonists- used in combination with MTX. Has a risk of serious bacterial infections, opportunistic fungal infection &amp; reactivation of latent TB. The TNF-α inhibitors are <strong>adalimumab,</strong> golimumab, etanercept, infliximab, and certolizumab.</li>\n<li>Abatacept- a T-cell costimulation inhibitor, used in combination with MTX, leflunomide, etc.</li>\n<li>Rituximab- an <strong>anti-CD20</strong> antibody. Used in refractory disease in combination with MTX.</li>\n<li>Anakinra- an<strong> IL-1</strong> receptor <strong>antagonist</strong>. It should not be combined with anti-TNF alpha.</li>\n<li><strong>IL-6</strong> receptor <strong>antagonists</strong>- tocilizumab and sarilumab are used as monotherapy or combination therapy in moderate to severe disease.  </li>\n</ul>\n<p><span><strong>- Small molecules: </strong></span></p>\n<ul>\n<li>Janus kinase inhibitors: <strong>Tofacitinib</strong>, baricitinib, and upadacitinib are used as monotherapy or combination therapy.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1310",
      "difficulty": "medium"
    },
    {
      "text": "You are using TNF alpha inhibitors in the treatment of a patient with rheumatoid arthritis. Which of the following is not true regarding these drugs?",
      "choices": [
        {
          "id": 1,
          "text": "They can also be used in the treatment of plaque psoriasis"
        },
        {
          "id": 2,
          "text": "They can be used in the treatment of psoriatic arthritis"
        },
        {
          "id": 3,
          "text": "They can be used in the treatment of lymphomas"
        },
        {
          "id": 4,
          "text": "They can be used in the treatment of ulcerative colitis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>TNF-&alpha; inhibitors are not used in the treatment of lymphomas.</p>\n<p>Despite their benefits, multiple <strong>potential adverse effects</strong>&nbsp;following the use of TNF-alpha inhibitors have been reported. These include:</p>\n<ul>\n<li class=\"bulletIndent1\"><strong>Malignancy (lymphoma)</strong></li>\n<li class=\"bulletIndent1\">Injection site reactions</li>\n<li class=\"bulletIndent1\">Infusion reactions</li>\n<li class=\"bulletIndent1\">Opportunistic infections.</li>\n</ul>\n<p class=\"p1\">TNF-&alpha; inhibitors can be used in the treatment of:</p>\n<ol>\n<li class=\"p1\">Rheumatoid arthritis</li>\n<li class=\"p1\">Ankylosing spondylitis</li>\n<li class=\"p1\">Crohn's disease</li>\n<li class=\"p1\">Ulcerative colitis</li>\n<li class=\"p1\">Plaque psoriasis</li>\n<li class=\"p1\">Psoriatic arthritis.</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4365",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged man with rheumatoid arthritis on treatment with methotrexate presents to your OPD complaining of no improvement in his condition. Which of the following is an IL-1 receptor antagonist that can you prescribe for him?",
      "choices": [
        {
          "id": 1,
          "text": "Anakinra"
        },
        {
          "id": 2,
          "text": "Rituximab"
        },
        {
          "id": 3,
          "text": "Tofacitinib"
        },
        {
          "id": 4,
          "text": "Golimumab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>IL-1 receptor antagonist</strong> that is used in the treatment of rheumatoid arthritis is <strong>anakinra</strong>.</p>\n<p>Anakinra is a <strong>biological&nbsp;DMARD</strong>&nbsp;(Disease Modifying Anti-Rheumatoid Drug) used in the treatment of rheumatoid arthritis. All biological DMARDs downregulate the immune system and can lead to adverse effects like opportunistic infections and flaring of latent TB.</p><hr><h3>Related Pearl: Important drugs for rheumatoid arthritis</h3><p><strong>1) NSAIDs - </strong>analgesic and anti-inflammatory, used as <strong>adjunctive</strong> for management of uncontrollable <strong>symptoms</strong> and in acute <strong>flares.</strong></p>\n<p dir=\"ltr\"><strong>2) Glucocorticoids - </strong>used in acute <strong>flare</strong> for rapid control and as <strong>initial therapy</strong> before the onset of action of DMARDs. Chronic administration of low doses is needed in patients with inadequate response to DMARDs.</p>\n<ul>\n<li dir=\"ltr\">\n<p>Prednisolone - oral</p>\n</li>\n<li dir=\"ltr\">\n<p>Triamcinolone - intraarticular<br /> </p>\n</li>\n</ul>\n<p><strong><span>3) DMARDs - </span></strong><span>disease-modifying anti-rheumatoid drugs:</span></p>\n<p> </p>\n<p><strong>- Conventional DMARDs:</strong></p>\n<ul>\n<li dir=\"ltr\">Methotrexate (MTX)- is an antifolate drug. The DMARD of <strong>choice</strong> and the anchor drug for combination therapy. Regular <strong>LFT</strong> monitoring is required.</li>\n<li dir=\"ltr\">Hydroxychloroquine- is used as <strong>monotherapy</strong> for <strong>early</strong> and <strong>mild</strong> disease and in combination with other DMARDs for severe cases.</li>\n<li dir=\"ltr\">Sulfasalazine- is a salicylate. It <strong>reduces</strong> the radiographic <strong>progression</strong> of the disease.</li>\n<li dir=\"ltr\">Leflunomide- is a pyrimidine synthase inhibitor used as an <strong>alternative</strong> to MTX.</li>\n</ul>\n<p><span><strong>- Biologicals:</strong></span></p>\n<ul>\n<li>TNF-α antagonists- used in combination with MTX. Has a risk of serious bacterial infections, opportunistic fungal infection &amp; reactivation of latent TB. The TNF-α inhibitors are <strong>adalimumab,</strong> golimumab, etanercept, infliximab, and certolizumab.</li>\n<li>Abatacept- a T-cell costimulation inhibitor, used in combination with MTX, leflunomide, etc.</li>\n<li>Rituximab- an <strong>anti-CD20</strong> antibody. Used in refractory disease in combination with MTX.</li>\n<li>Anakinra- an<strong> IL-1</strong> receptor <strong>antagonist</strong>. It should not be combined with anti-TNF alpha.</li>\n<li><strong>IL-6</strong> receptor <strong>antagonists</strong>- tocilizumab and sarilumab are used as monotherapy or combination therapy in moderate to severe disease.  </li>\n</ul>\n<p><span><strong>- Small molecules: </strong></span></p>\n<ul>\n<li>Janus kinase inhibitors: <strong>Tofacitinib</strong>, baricitinib, and upadacitinib are used as monotherapy or combination therapy.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0056",
      "difficulty": "easy"
    },
    {
      "text": "Which is the monoclonal antibody approved for the treatment of rheumatoid arthritis?",
      "choices": [
        {
          "id": 1,
          "text": "Durvalumab"
        },
        {
          "id": 2,
          "text": "Sarilumab"
        },
        {
          "id": 3,
          "text": "Nivolumab"
        },
        {
          "id": 4,
          "text": "Pembrolizumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The monoclonal antibody approved for the treatment of rheumatoid arthritis is <strong>sarilumab</strong>.</p>\n<p>It is an <strong>IL-6 receptor antagonist</strong>&nbsp;indicated for the treatment of adults with <strong>moderate to severe rheumatoid arthritis</strong> who show inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).</p>\n<p>Option A:&nbsp;<strong>Durvalumab</strong> is an anti PD-L1 antibody approved for <strong>metastatic urothelial cancer.</strong></p>\n<p>Option C:&nbsp;<strong>Nivolumab</strong> is a fully human monoclonal IgG4 antibody that blocks the interaction between PD-1 (Programmed cell Death-1) receptor and its ligands.</p>\n<p>Option D:&nbsp;<strong>Pembrolizumab</strong> (formerly called lambrolizumab or MK-3475) is a humanized monoclonal IgG4-&kappa; isotype antibody that blocks the interaction between PD-1 and its ligands. Nivolumab and pembrolizumab are used to treat <strong>advanced melanoma.</strong></p><hr><h3>Related Pearl: Important drugs for rheumatoid arthritis</h3><p><strong>1) NSAIDs - </strong>analgesic and anti-inflammatory, used as <strong>adjunctive</strong> for management of uncontrollable <strong>symptoms</strong> and in acute <strong>flares.</strong></p>\n<p dir=\"ltr\"><strong>2) Glucocorticoids - </strong>used in acute <strong>flare</strong> for rapid control and as <strong>initial therapy</strong> before the onset of action of DMARDs. Chronic administration of low doses is needed in patients with inadequate response to DMARDs.</p>\n<ul>\n<li dir=\"ltr\">\n<p>Prednisolone - oral</p>\n</li>\n<li dir=\"ltr\">\n<p>Triamcinolone - intraarticular<br /> </p>\n</li>\n</ul>\n<p><strong><span>3) DMARDs - </span></strong><span>disease-modifying anti-rheumatoid drugs:</span></p>\n<p> </p>\n<p><strong>- Conventional DMARDs:</strong></p>\n<ul>\n<li dir=\"ltr\">Methotrexate (MTX)- is an antifolate drug. The DMARD of <strong>choice</strong> and the anchor drug for combination therapy. Regular <strong>LFT</strong> monitoring is required.</li>\n<li dir=\"ltr\">Hydroxychloroquine- is used as <strong>monotherapy</strong> for <strong>early</strong> and <strong>mild</strong> disease and in combination with other DMARDs for severe cases.</li>\n<li dir=\"ltr\">Sulfasalazine- is a salicylate. It <strong>reduces</strong> the radiographic <strong>progression</strong> of the disease.</li>\n<li dir=\"ltr\">Leflunomide- is a pyrimidine synthase inhibitor used as an <strong>alternative</strong> to MTX.</li>\n</ul>\n<p><span><strong>- Biologicals:</strong></span></p>\n<ul>\n<li>TNF-α antagonists- used in combination with MTX. Has a risk of serious bacterial infections, opportunistic fungal infection &amp; reactivation of latent TB. The TNF-α inhibitors are <strong>adalimumab,</strong> golimumab, etanercept, infliximab, and certolizumab.</li>\n<li>Abatacept- a T-cell costimulation inhibitor, used in combination with MTX, leflunomide, etc.</li>\n<li>Rituximab- an <strong>anti-CD20</strong> antibody. Used in refractory disease in combination with MTX.</li>\n<li>Anakinra- an<strong> IL-1</strong> receptor <strong>antagonist</strong>. It should not be combined with anti-TNF alpha.</li>\n<li><strong>IL-6</strong> receptor <strong>antagonists</strong>- tocilizumab and sarilumab are used as monotherapy or combination therapy in moderate to severe disease.  </li>\n</ul>\n<p><span><strong>- Small molecules: </strong></span></p>\n<ul>\n<li>Janus kinase inhibitors: <strong>Tofacitinib</strong>, baricitinib, and upadacitinib are used as monotherapy or combination therapy.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5508",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a Janus kinase inhibitor approved for use in rheumatoid arthritis?",
      "choices": [
        {
          "id": 1,
          "text": "Ruxolitinib"
        },
        {
          "id": 2,
          "text": "Baricitinib"
        },
        {
          "id": 3,
          "text": "Denosumab"
        },
        {
          "id": 4,
          "text": "Dasatinib"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Baricitinib&nbsp;</strong>was&nbsp;approved for use in patients with rheumatoid arthritis. It is a<strong>&nbsp;<strong>Janus kinase inhibitor.</strong></strong></p>\n<p>Oral Janus kinase inhibitors for rheumatoid arthritis and upadacitinib and tofacitinib.</p>\n<p>Option A: <strong>Ruxolitinib</strong> is a&nbsp;<strong>Janus kinase inhibitor</strong>, approved for use in various forms of <strong>myelofibrosis,</strong> <strong>polycythemia vera</strong>, and acute graft vs host disease.</p>\n<p>Option C: <strong>Denosumab</strong> is a RANK-L inhibitor that is approved for the treatment of <strong>osteoporosis.</strong></p>\n<p>Option D: <strong>Dasatinib</strong> and ponatinib are BCR-ABL tyrosine kinase inhibitors indicated for the treatment of <strong>CML.</strong>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1302",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is not an indication for the use of corticosteroids in the treatment of rheumatoid arthritis?",
      "choices": [
        {
          "id": 1,
          "text": "Management of acute disease flares while on therapy with DMARDs"
        },
        {
          "id": 2,
          "text": "As bridging therapy initially, till DMARDs take effect"
        },
        {
          "id": 3,
          "text": "Chronic therapy in cases that cannot be controlled with DMARDs"
        },
        {
          "id": 4,
          "text": "As monotherapy for the treatment of rheumatoid arthritis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\">Glucocorticoids are not used as monotherapy for the treatment of rheumatoid arthritis (RA).</p>\n<p class=\"p1\"><strong>High doses </strong>of <strong>glucocorticoids</strong> may be needed to treat <strong>severe extraarticular manifestations</strong> of RA.</p>\n<p class=\"p1\">Intraarticular injection of triamcinolone can be considered for one/few actively inflamed joints.</p>\n<p class=\"p1\">Option A: A <strong>burst</strong> of glucocorticoids for 1-2 weeks may be prescribed to manage <strong>acute disease flares</strong>.&nbsp;</p>\n<p class=\"p1\">Option B:&nbsp;They may be administered as <strong>bridging therapy</strong> initially to achieve rapid disease control till DMARDs take effect, which may take several weeks or even months.&nbsp;</p>\n<p class=\"p1\">Option C: <strong>Chronic therapy</strong> with <strong>low doses</strong> may be needed to control the disease in patients with an <strong>inadequate response to DMARD</strong> therapy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1323",
      "difficulty": "medium"
    }
  ]
}